Attovia 制药
ATTO
13.73
-1.05
-7.10%
Attovia 制药
US · ATTO
#3464 按市值排名
上市于 2026
13.73
-1.05
-7.10%
实时 - 追踪5344个代码 - 心跳于350秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了10家。
- 机构持股总比例上升了48.6个百分点。
机构持股
- 机构持股比例
- 48.59% +48.59pp
- 机构数量
- 10 +10
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund31.45%
Public Company10.47%
Mutual Fund4.51%
Hedge Fund2.15%
Individual/Insider1.58%
Other49.83%
主要股东 截至 2026-08-07
Frazier Life Sciences Management, LP
15.27% · 6.97M 股
venBio LLC
9.16% · 4.18M 股
Alamar Biosciences, Inc.
7.07% · 3.23M 股
Deep Track Capital, LP
7.03% · 3.21M 股
Goldman Sachs Asset Management, L.P.
4.31% · 1.97M 股
Sanofi
2.37% · 1.08M 股
Redmile Group, LLC
2.15% · 982.85K 股
Tao Fu
1.20% · 548.56K 股
The Goldman Sachs Group, Inc.
1.03% · 468.57K 股
Petter Veiby
0.23% · 104.95K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪27份申报 · 15次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.27% |
| Tao Fu | Chief Executive Officer | 1.20% |
| Petter Veiby | Chief Scientific Officer | 0.23% |
| Angie You | Independent Director | 0.12% |
| Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary | 0.02% |
| Hubert Chen | Chief Medical Officer | 0.01% |
| Sanofi | -- | -- |
| Mitchell Gold | Independent Director | -- |
| Goldman Sachs Asset Management, L.P. | -- | -- |
| Redmile Group, LLC | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-05 | Sanofi | -- | Private Acquisition | +300,000 | $17.00 |
| 2026-08-05 | Sanofi | -- | Derivative Exercise and Retained | +782,855 | -- |
| 2026-08-05 | Redmile Group, LLC | -- | Private Acquisition | +200,000 | $17.00 |
| 2026-08-05 | Redmile Group, LLC | -- | Derivative Exercise and Retained | +782,854 | -- |
| 2026-08-05 | venBio LLC | -- | Private Acquisition | +382,352 | $17.00 |
| 2026-08-05 | venBio LLC | -- | Derivative Exercise and Retained | +3,799,015 | -- |
| 2026-08-05 | Deep Track Capital, LP | -- | Derivative Exercise and Retained | +1,957,138 | -- |
| 2026-08-05 | Frazier Life Sciences Management, LP | -- | Private Acquisition | +588,235 | $17.00 |
| 2026-08-05 | Frazier Life Sciences Management, LP | -- | Derivative Exercise and Retained | +5,490,629 | -- |
| 2026-08-04 | Goldman Sachs Asset Management, L.P. | -- | Open Market Derivative Acquisiti | +105,807 | -- |
| 2026-08-03 | Sanofi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Mitchell Gold | Independent Director | Other Derivative Acquisition | +27,000 | $17.00 |
| 2026-08-03 | Mitchell Gold | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Angie You | Independent Director | Other Derivative Acquisition | +27,000 | $17.00 |
| 2026-08-03 | John Smither | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Hubert Chen | Chief Medical Officer | Other Derivative Acquisition | +140,000 | $17.00 |
| 2026-08-03 | Broad Street Principal Investments, L.L.C. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Tao Fu | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Alamar Biosciences, Inc. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-03 | Zaneta Odrowaz | Chief Business Officer, Treasurer & Secretary | Other Derivative Acquisition | +140,000 | $17.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:10 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Attovia 制药 讨论区 0 条评论